Article Versions Notes

Mizushige T, Kobori H, Hitomi H, Nishijima Y, Tomoda F, Morimoto S, Kohno M, Nishiyama A. Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients. International Journal of Molecular Sciences. 2016; 17(11):1800. https://doi.org/10.3390/ijms17111800

Mizushige, Tomoko, Hiroyuki Kobori, Hirofumi Hitomi, Yoko Nishijima, Fumihiro Tomoda, Satoshi Morimoto, Masakazu Kohno, and Akira Nishiyama. 2016. "Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients" International Journal of Molecular Sciences 17, no. 11: 1800. https://doi.org/10.3390/ijms17111800

Mizushige, T., Kobori, H., Hitomi, H., Nishijima, Y., Tomoda, F., Morimoto, S., Kohno, M., & Nishiyama, A. (2016). Urinary Angiotensinogen Could Be a Prognostic Marker of the Renoprotection of Olmesartan in Metabolic Syndrome Patients. International Journal of Molecular Sciences, 17(11), 1800. https://doi.org/10.3390/ijms17111800